• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173180 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
/ C9 V' u! I! b3 O" S9 C1 _( K1 m0 d! U& G5 u' [' i7 m
) t4 S3 h) T: L  }/ o+ w6 G
Sub-category:
3 \* \5 R: T4 ?/ QMolecular Targets
$ k) F! C- j( j+ L$ E3 W
" u$ G! c- C7 p- n) r! Z2 K# A( Z+ Y$ ?0 {
Category:
9 ~5 o% t$ J: R0 Q- CTumor Biology 9 Z% ^% R% S, H( i6 Z- g
4 m# ]- ]$ G" w. u+ O/ D( s
3 S' R% _( b' F, Y. E/ E
Meeting:
2 x8 n7 o1 F0 M# y% a; J2011 ASCO Annual Meeting
& \  Q4 A0 q. |0 F; f; D6 S) x; H( _

  N6 F( o$ }: s. ?" |: j3 @Session Type and Session Title:
/ P' y8 m+ E/ F6 N  q  ePoster Discussion Session, Tumor Biology
0 J/ r& r6 g1 b, _7 d# x
; p  s! x. d  M6 A( L' y# q/ y6 L* m. x" `7 m" q/ [
Abstract No:! C: ]7 _, H' m$ z
10517
0 y; }. i4 G; e  u5 \
1 T3 K2 E' N: p# N
" G& x0 c9 d- \3 ^) n6 r% I4 B$ Z* {Citation:9 u: M: B9 K5 Z" _0 z$ q" u
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 e% A6 b5 ~6 c9 T4 N3 H1 W
3 @# ^) P9 p8 @5 m; r( l* u
" l4 J" t' ~' U* ^Author(s):
5 K8 Q+ H4 r$ I4 l; AJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
- z2 F8 h" Q) L0 t4 [+ E2 H7 @  `: I" I( u# p* J
* o6 w; K* Q( Z3 x) t8 C) z" t
9 Z1 F9 z1 ]  Q0 X: W
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings." @9 U0 Y% x9 I- U6 I- J# `/ P9 E

% j+ ]; ^+ r, @9 |1 N0 bAbstract Disclosures8 |/ s6 f8 m6 j7 n" }7 ~

& S7 [8 G; w: c- U; j. pAbstract:) v4 n" P6 F- \' X% b" N

+ i/ v4 _1 ?8 K+ r
6 }1 ]) O5 R# L$ _/ ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 V& V  |7 Q) m1 s7 d. S5 U6 [  m' ?

% z7 A8 ~) {' V0 q9 {
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
! o( X" M& s  l, c6 J: a0 u+ p( k没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
" f, s8 A" g  a
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
) L; s7 T; n2 S! t$ E! R易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。7 E. A0 {' M& s6 R" A! H7 ]" L
ALK一个指标医院要900多 ...
# F% }/ G* W" `' |% r/ ~
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
; L1 p9 @8 W4 z$ L. t7 O' d5 P0 C* q; |  `/ }: L* k7 `7 |+ `
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表